FDA
-
-
-
-
-
-
-
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
-
-
-
-
-
-
-
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
-
-
-
-
-
-
-
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
-
-
-
-
-
-
-
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
-
-
-
-
-
-
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Kura receives $135 million milestone payment from Kyowa Kirin
-
-
-
-
-
-
-
Kura Oncology receives FDA approval for blood cancer drug
-
328,337 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

